Brokerages forecast that Agile Therapeutics Inc (NASDAQ:AGRX) will post ($0.15) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.13). Agile Therapeutics reported earnings of ($0.22) per share during the same quarter last year, which would suggest a positive year over year growth rate of 31.8%. The business is expected to announce its next quarterly earnings results on Monday, November 5th.
On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.63) to ($0.56). For the next year, analysts expect that the business will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.94) to ($0.41). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.01.
In other Agile Therapeutics news, insider Life Sciences Maste Perceptive sold 298,628 shares of the business’s stock in a transaction that occurred on Thursday, July 26th. The stock was sold at an average price of $0.30, for a total value of $89,588.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.30% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. A.R.T. Advisors LLC increased its stake in shares of Agile Therapeutics by 82.3% during the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after buying an additional 29,995 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after buying an additional 55,937 shares during the period. Renaissance Technologies LLC increased its stake in shares of Agile Therapeutics by 76.3% during the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after buying an additional 343,290 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Agile Therapeutics by 17.0% during the first quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after buying an additional 487,400 shares during the period. 52.00% of the stock is currently owned by hedge funds and other institutional investors.
AGRX stock traded up $0.13 during midday trading on Friday, hitting $0.74. The company had a trading volume of 7,710,743 shares, compared to its average volume of 1,364,471. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $5.37. The company has a market capitalization of $12.60 million, a P/E ratio of -0.81 and a beta of 1.43.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Further Reading: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.